Supplementary appendix

Table S1: Predictors of visit frequency controlling for proportion of patients receiving efavirenz-based antiretroviral therapy.

	VL IRR (95% CI)	CD4 IRR (95% CI)	Clinical IRR (95% CI)
Univariable analyses			
Proportion of patients receiving EFV per 100% increase	0.39 (0.38-0.41)	0.31 (0.30-0.31)	0.86 (0.85-0.86)
Multivariable analyses			
Calendar year			
2004-2007	1	1	1
2008-2011	0.92 (0.91-0.93)	0.93 (0.92-0.94)	0.90 (0.89-0.91)
2012-2015	0.78 (0.78-0.79)	0.71 (0.71-0.72)	0.81 (0.80-0.82)
2016-2018	0.74 (0.74-0.75)	0.88 (0.87-0.89)	0.77 (0.76-0.78)
Year on ART			
2	1.00 (1.00-1.00)	1.00 (1.00-1.00)	1.00 (1.00-1.00)
3	0.96 (0.96-0.96)	0.97 (0.96-0.97)	0.94 (0.94-0.95)
4	0.95 (0.94-0.95)	0.92 (0.91-0.92)	0.93 (0.93-0.94)
5+	0.92 (0.91-0.92)	0.86 (0.86-0.87)	0.91 (0.90-0.91)
Age at ART initiation			
15-24	1	1	1
25-34	0.98 (0.97-0.99)	0.99 (0.98-1.00)	0.97 (0.96-0.98)
35-49	0.98 (0.97-0.99)	1.01 (1.00-1.02)	0.97 (0.96-0.98)
50+	1.00 (0.99-1.02)	1.04 (1.03-1.05)	1.01 (1.00-1.02)
Gender			
Male	1	1	1
Female	1.01 (1.01-1.02)	0.99 (0.99-1.00)	1.03 (1.03-1.04)
WHO clinical stage			
1	1	1	1
2	1.00 (0.99-1.02)	1.03 (1.02-1.03)	1.01 (1.00-1.02)
3	1.03 (1.02-1.03)	1.02 (1.02-1.03)	1.00 (1.00-1.01)
4	1.02 (1.01-1.03)	1.04 (1.03-1.05)	1.05 (1.03-1.06)
Unknown	1.04 (1.00-1.08)	1.06 (1.06-1.07)	0.99 (0.99-1.00)
CD4 at ART initiation			
<200	1	1	1
200-349	0.96 (0.96-0.97)	0.95 (0.94-0.95)	1.01 (1.00-1.02)
350-500	0.96 (0.94-0.98)	0.93 (0.92-0.94)	1.01 (0.99-1.02)
>500	0.94 (0.92-0.96)	0.90 (0.89-0.91)	1.00 (0.98-1.02)
Unknown	0.99 (0.98-1.00)	0.97 (0.96-0.98)	1.01 (1.01-1.02)
Proportion of patients receiving EFV per 100% increase	0.64 (0.62-0.66)	0.56 (0.55-0.57)	0.88 (0.88-0.89)

Data are incidence rate ratios (IRR) and 95% confidence intervals (CIs) from univariable and multivariable Poisson models. Clinical, Clinical monitoring; CD4, CD4 monitoring; VL, Viral-load monitoring. Calendar year and years since antiretroviral therapy (ART) initiation were assessed at each visit. CD4 cell count, WHO clinical stage, and age were measured at initiation of antiretroviral therapy (ART). Proportion of patients receiving efavirenz (EFV)-based antiretroviral therapy regimen at a treatment program in calendar year. Multivariable model is adjusted for all variables shown in the table and treatment program.

Figure S1: Proportion of patients receiving efavirenz-based antiretroviral therapy.